About Us

Founded in 2017, InxMed is a late-stage biotechnology company dedicated to transforming treatment paradigms in oncology. We are committed to addressing a core challenge in cancer therapy: treatment resistance driven by the tumor’s intrinsic defense system. Our strategy focuses on critical signaling hubs shared across multiple tumor types—most notably the focal adhesion kinase (FAK) and integrin pathways—which play pivotal roles in tumor cell survival and contribute to treatment failure across various therapeutic modalities. In parallel, we target cancer-associated fibroblasts (CAFs) to dismantle the protective barrier around tumor cells. Through these integrated efforts, we aim to redefine cancer treatment and pioneer new frontiers in therapeutic innovation.


InxMed has established a highly differentiated pipeline focused on overcoming tumor defense mechanisms. Our lead program, ifebemtinib, is currently in the registrational stage and has been granted Breakthrough Therapy Designation by the China National Medical Products Administration (NMPA) as well as Fast Track Designation by the U.S. FDA. Additionally, several highly innovative preclinical candidates, which demonstrate synergy with our clinical-stage assets, are advancing toward clinical studies.


Members of InxMed’s management team have held senior R&D and commercial roles in top-tier multinational pharmaceutical companies. They possess extensive experience in advancing more than 100 clinical assets into clinical development and have led over 20 clinical programs resulting in New Drug Application (NDA) approvals in both China and the United States.
InxMed operates in both the United States and China. We are a passionate, energetic, and creative team united by a strong belief in doing "extraordinary things" to transform cancer treatment.

这里是标题一h1占位文字